Skip to main content
. 2024 Sep 10;19:9333–9349. doi: 10.2147/IJN.S473463

Figure 1.

Figure 1

Schematic diagram of ERFe3O4 NPs for tumor immunotherapy. (a) EFe3O4 NPs was prepared by loading emodin with hollow Fe3O4 NPs, which was further encapsulated by gRBCs to obtain ERFe3O4 NPs. (b) The ERFe3O4 NPs could target TAMs by binding to M2-like TAMs with high expression of galectin (Mgl). The release of emodin inhibited the production of lactate, with which Fe3O4 NPs synergistically to reprogram M2 TAMs into M1 TAMs for eliminating tumors.